Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease.
Since the discovery that 5-aminosalicylic acid (5-ASA) is the active moiety of sulphasalazine in the treatment of chronic inflammatory bowel disease, several new 5-ASA based drugs have been developed. These consist either of slow- or delayed-release formulations of plain 5-ASA or sulpha-free azo compounds of 5-ASA. The different formulations and compounds have varying bioavailabilities, which makes it possible to use them alternatively in different clinical situations. A review of the literature is given, together with suggestions as to how the new drugs might be used in different clinical situations.
Järnerot
G
G
Department of Medicine, Orebro Medical Center Hospital, Sweden.
D000284:Administration, Oral; D000287:Administration, Topical; D000636:Aminosalicylic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D008297:Male; D019804:Mesalamine
D000636:Aminosalicylic Acids; D019804:Mesalamine